Russian journal of anaesthesiology and reanimatology 2, 2019 Клинические рекомендации фар



Pdf көрінісі
бет29/31
Дата29.01.2023
өлшемі0,76 Mb.
#166675
1   ...   23   24   25   26   27   28   29   30   31
Байланысты:
Anestesiolog 2019 02 005

Cochrane Database Syst Rev
. 2015;(7):CD010555.
114. Huber A, Raio L, Alberio L, Ghezzi F, Surbek D. Recombinant human fac-
tor VIIa prevents hysterectomy in severe postpartum hemorrhage: single cen-
ter study. 
J Perinat Med
. 2011;40(1):43-49.
115. Phillips L, McLintock C, Pollock W, Gatt S, et al. Australian and New Zea-
land Haemostasis Registry. Recombinant activated factor VII in obstetric 
hemorrhage: experiences from the Australian and New Zealand Haemosta-
sis Registry. 
Anesth Analg
. 2009;109(6):1908-1915.
116. Lavigne-Lissalde G, Aya A, Mercier F, Roger-Christoph S, et al. Recom-
binant human FVIIa for reducing the need for invasive second-line thera-
pies in severe refractory postpartum hemorrhage: a multicenter, randomized, 
open controlled trial. 
J Thromb Haemost
. 2015;13(4):520-529.
117. Franchini M, Manzato F, Salvagno G, Lippi G. Potential role of recombi-
nant activated factor VII for the treatment of severe bleeding associated with 
disseminated intravascular coagulation: a systematic review. 
Blood Coagul Fi-
brinolysis
. 2007;18(7):589-593.
118. Brenner B, Wiis J. Experience with recombinant-activated factor VII in 30 
patients with congenital factor VII deficiency. 
Hematology
. 2007;12(1):55-62.
119. Shah N, Chong S, Yusoff S, Mazlan M, et al. Recombinant activated factor 
VII (rFVIIa) in refractory haemorrhage for non-haemophiliacs: an eleven-
year single-centre experience. 
BMC Hematol
. 2018;18:34.
120. Ahonen J. The role of recombinant activated factor VII in obstetric hemor-
rhage. 
Curr Opin Anaesthesiol
. 2012;25(3):309-314.
121. Kalina M, Tinkoff G, Fulda G. Massive postpartum hemorrhage: recombi-
nant factor VIIa use is safe but not effective. 
Del Med J
. 2011;83(4):109-113.
122. Dutta T, Verma S. Rational Use of Recombinant Factor VIIa in Clinical 
Practice. 
Indian J Hematol Blood Transfus
. 2014;30(2):85-90.
123. Bolliger D, Mauermann E, Tanaka K. Thresholds for Perioperative Administra-
tion of Hemostatic Blood Components and Coagulation Factor Concentrates: 
An Unmet Medical Need. 
J Cardiothorac Vasc Anesth
. 2015;29(3):768-776.
124. Knight M, Fitzpatrick K, Kurinczuk J, Tuffnell D. Use of recombinant factor 
VIIa in patients with amniotic fluid embolism. 
Anesthesiology
. 2012;117:423.
125. Neb H, Zacharowski K, Meybohm P. Strategies to reduce blood product uti-
lization in obstetric practice. 
Curr Opin Anaesthesiol
. 2017;30(3):294-299.
126. Godier A, Greinacher A, Faraoni D, Levy J, Samama M. Use of factor con-
centrates for the management of perioperative bleeding: guidance from the 
SSC of the ISTH. 
J Thromb Haemost
. 2018;16(1):170-174.
127. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno G, Tar-
gher G, Lippi G. The use of recombinant activated FVII in postpartum hem-
orrhage. 
Clin Obstet Gynecol
. 2010;53(1):219-227.
128. Zarychanski R, Abou-Setta A, Kanji S, Turgeon A, et al. Canadian 
Critical Care Trials Group. The efficacy and safety of heparin in pa-
tients with sepsis: a systematic review and metaanalysis. 
Crit Care Med

2015;43(3):511-518.
129. Bain E, Wilson A, Tooher R, Gates S, Davis L, Middleton P. Prophylax-
is for venous thromboembolic disease in pregnancy and the early postnatal 
period. 
Cochrane Database Syst Rev
. 2014;(2):CD001689.
130. Villani M, Ageno W, Grandone E, Dentali F. The prevention and treatment 
of venous thromboembolism in pregnancy. 
Expert Rev Cardiovasc Ther

2017;15(5):397-402.
131. Wada H, Matsumoto T, Yamashita Y. Diagnosis and treatment of dissemi-
nated intravascular coagulation (DIC) according to four DIC guidelines. 


Достарыңызбен бөлісу:
1   ...   23   24   25   26   27   28   29   30   31




©engime.org 2024
әкімшілігінің қараңыз

    Басты бет